Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.

Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.

MUC1 is associated with cellular transformation and tumorigenicity and is considered as an important tumor-associated antigen (TAA) for cancer therapy. We previously reported that anti-MUC1 monoclonal antibody C595 (MAb C595) plus docetaxel (DTX) increased efficacy of DTX alone and caused cultured h...

Full description

Bibliographic Details
Main Authors: Li Wang, Hongmin Chen, Mohammad H Pourgholami, Julia Beretov, Jingli Hao, Hongtu Chao, Alan C Perkins, John H Kearsley, Yong Li
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3170300?pdf=render

Internet

http://europepmc.org/articles/PMC3170300?pdf=render

Similar Items